Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that it has entered into its first concierge medicine contract with LEAA Health. The contract provides LEEA Health’s membership-based patients access to groundbreaking esophageal precancer testing using Lucid’s EsoGuard Esophageal DNA Test. This expands LEAA Health’s enhanced personalized care services, which it offers to its patients on a cash-pay basis.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue